Literature DB >> 24354850

Transcriptionally correlated subcellular dynamics of MBNL1 during lens development and their implication for the molecular pathology of myotonic dystrophy type 1.

Stewart M Coleman1, Alan R Prescott2, Judith E Sleeman1.   

Abstract

DM1 (myotonic dystrophy type 1) is caused by elongation of a CTG repeat in the DMPK (dystrophia myotonica-protein kinase) gene. mRNA transcripts containing these CUGexp (CUG expansion) repeats form accumulations, or foci, in the nucleus of the cell. The pathogenesis of DM1 is proposed to result from inappropriate patterns of alternative splicing caused by sequestration of the developmentally regulated alternative splicing factor MBNL1 (muscleblind-like 1) by these foci. Since eye lens cataract is a common feature of DM1 we have examined the distribution and dynamics of MBNL1 in lens epithelial cell lines derived from patients with DM1. The results of the present study demonstrate that only a small proportion of nuclear MBNL1 accumulates in CUGexp pre-mRNA foci. MBNL1 is, however, highly mobile and changes localization in response to altered transcription and splicing activity. Moreover, immunolocalization studies in lens sections suggest that a change in MBNL1 distribution is important during lens growth and differentiation. Although these data suggest that the loss of MBNL1 function due to accumulation in foci is an unlikely explanation for DM1 symptoms in the lens, they do demonstrate a strong relationship between the subcellular MBNL1 localization and pathways of cellular differentiation, providing an insight into the sensitivity of the lens to changes in MBNL1 distribution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24354850     DOI: 10.1042/BJ20130870

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  6 in total

1.  Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis.

Authors:  Albert W Cheng; Jiahai Shi; Piu Wong; Katherine L Luo; Paula Trepman; Eric T Wang; Heejo Choi; Christopher B Burge; Harvey F Lodish
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

2.  Myotonic dystrophy type 1 presenting with dyspnea: A case report.

Authors:  Yu-Xi Jia; Chun-Ling Dong; Jia-Wei Xue; Xiao-Qin Duan; Ming-Yu Xu; Xiao-Min Su; Ping Li
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

3.  Three-dimensional imaging in myotonic dystrophy type 1: Linking molecular alterations with disease phenotype.

Authors:  Alfonsina Ballester-Lopez; Judit Núñez-Manchón; Emma Koehorst; Ian Linares-Pardo; Miriam Almendrote; Giuseppe Lucente; Nicolau Guanyabens; Marta Lopez-Osias; Adrián Suárez-Mesa; Shaliza Ann Hanick; Jakub Chojnacki; Alejandro Lucia; Guillem Pintos-Morell; Jaume Coll-Cantí; Alicia Martínez-Piñeiro; Alba Ramos-Fransi; Gisela Nogales-Gadea
Journal:  Neurol Genet       Date:  2020-07-21

4.  Muscleblind-like 1 is required for normal heart valve development in vivo.

Authors:  Ryan J Coram; Samantha J Stillwagon; Anuradha Guggilam; Michael W Jenkins; Maurice S Swanson; Andrea N Ladd
Journal:  BMC Dev Biol       Date:  2015-10-15       Impact factor: 1.978

5.  Transplantation studies reveal internuclear transfer of toxic RNA in engrafted muscles of myotonic dystrophy 1 mice.

Authors:  Ricardo Mondragon-Gonzalez; Karim Azzag; Sridhar Selvaraj; Ami Yamamoto; Rita C R Perlingeiro
Journal:  EBioMedicine       Date:  2019-08-21       Impact factor: 11.205

6.  Condensation properties of stress granules and processing bodies are compromised in myotonic dystrophy type 1.

Authors:  Selma Gulyurtlu; Monika S Magon; Patrick Guest; Panagiotis P Papavasiliou; Kim D Morrison; Alan R Prescott; Judith E Sleeman
Journal:  Dis Model Mech       Date:  2022-08-02       Impact factor: 5.732

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.